Pfizer's Phase 2 Study Demonstrates Safety, Tolerability and Immunogenicity of TRUMENBA® When Coadministered with Meningococcal A, C, Y and W-135 Polysaccharide Conjugate (MCV4) and Tetanus, Diphtheria and Pertussis (Tdap) Vaccines in Adolescents
October 09, 2015 at 13:50 PM EDT
Pfizer Inc. (NYSE: PFE) announced today that researchers presented for the first time data from a randomized, controlled Phase 2 study ...
